‘Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch.’
Arcinova, the UK-based multiservice contract development and manufacturing organisation, has been acquired by Quotient Sciences, the drug development and manufacturing accelerator.
The acquisition expands Quotient’s service portfolio and will enable the integration of drug substance, drug product and clinical testing capabilities under one organisation – extending the 12-month drug development timeline savings already delivered by Quotient’s flagship platform Translational Pharmaceuticals.
Professor Ian Shott, CBE, co-founder and executive chairman of Arcinova said; ‘Since inception, we set out to build a unique organisation that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility and the drive for customer service excellence are the cornerstones of both businesses.’
Quotient Sciences’ CEO Mark Egerton, PhD said; ‘I’d like to congratulate the Arcinova team on building an exciting business and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch.’
Both companies expressed gratitude to their respective equity partners; BGF, which has backed Arcinova’s growth since 2018 and will now exit the business and Premira, supporting Quotient Science’s growth plans.
This latest development for Arcinova has been warmly welcomed by SCI, where Arcinova has been a corporate partner since 2017.
Commenting, Karen Hobbs Head of Strategic Partnerships at SCI said; ‘Having worked with Arcinova as part of our Corporate Partnership scheme since 2017, we have been impressed by their growth and expanding capability within the team. The acquisition by Quotient Sciences represents another exciting step in the Arcinova journey, demonstrating an innovation-led approach and commitment to bringing life-changing medicines to market. We look forward to working with Arcinova and Quotient Sciences as they go through this transition, and we look forward to welcoming Quotient Sciences’ team to the SCI corporate network.’